AMANDA THOMAS: Open Payments
NPI 1326464769 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 59 payments from 16 companies in 2025. Trend: 2023 $834 · 2024 $941 · 2025 $1,352
Food & beverage: $1,352
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $344 |
| Regeneron Healthcare Solutions, Inc. | 17 | $257 |
| BioCryst US Sales Co., LLC | 7 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $163 |
| GlaxoSmithKline, LLC. | 3 | $68 |
| CSL Behring | 2 | $64 |
| Novartis Pharmaceuticals Corporation | 3 | $53 |
| GENZYME CORPORATION | 2 | $48 |
| Optinose US, Inc. | 2 | $43 |
| PFIZER INC. | 2 | $37 |
Products named: DUPIXENT, FASENRA, ORLADEYO, CUVITRU, TRELEGY ELLIPTA, Xhance, OCTAGAM IMMUNE GLOBULIN (HUMAN), XOLAIR.
Industry payments across TX — which companies pay providers there.
